- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07648953
Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors
This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.
Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Echo Warner, MPH, PhD, SB
- Numéro de téléphone: 801-244-7040
- E-mail: echo.warner@hci.utah.edu
Lieux d'étude
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Recrutement
- University of Utah
-
Contact:
- Echo Warner, MPH, PhD, SB
- Numéro de téléphone: 801-244-7040
- E-mail: echo.warner@hci.utah.edu
-
Chercheur principal:
- Echo Warner, MPH, PhD, SB
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.
- Currently use Facebook or willing to create a Facebook account to use for the duration of the study.
- At the time of enrollment, have not completed all recommended doses of the HPV vaccine.
Exclusion Criteria:
- Unable to speak and understand English.
- Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.
- Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: HPV Vaccination Education
Microvideos are designed to be <2 minutes long and to address key information on a topic in an engaging and concise manner.
HPV vaccine education will be provided to unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention.
|
To educate survivors of childhood cancers about a key cancer prevention strategy, HPV vaccination.
The core microvideos will focus on the 5 Ws of HPV vaccination: Who should get vaccinated, What HPV vaccination protects against, When to get vaccinated, Where to access the vaccine, Why it matters-designed particularly for cancer survivors.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Feasibility of Microvideo education
Délai: up to 4 weeks
|
Feasibility will be defined as ≥80% of participants completing the intervention and study surveys.
|
up to 4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Acceptability of Microvideo Education
Délai: up to 4 weeks
|
Acceptability will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
Satisfaction Acceptability of Microvideo Education
Délai: up to 4 weeks
|
Satisfaction will be summarized using means, standard deviations, and proportions of participants indicating strong agreement (scores ≥4 out of 5) with positive statements about the microvideos and platform. Scores range from 0-5, with higher scores indicating more positivity about the microvideos and platform, and lower scores indicating less positivity about the microvideos and platform. |
up to 4 weeks
|
|
HPV Vaccine Intention
Délai: up to 4 weeks
|
To assess HPV vaccine intention among unvaccinated emerging adult survivors of childhood cancer through a pilot quasi-experimental social media intervention. This outcome measure will report the count of participants who intended to receive the HPV Vaccine after the microvideo education. |
up to 4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Echo Warner, MPH, PhD, SB, Huntsman Cancer Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 198894
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .